Chimeric antigen receptors (CAR) are engineered fusion proteins designed to target T cells
to antigens expressed on cancer cells. CAR T cells are now an established treatment for …

Immunotherapy has been a remarkable clinical advancement in the treatment of cancer. T
cells are pivotal to the efficacy of current cancer immunotherapies, including immune …

Background In an analysis of the primary outcome of this phase 3 trial, patients with early
relapsed or refractory large B-cell lymphoma who received axicabtagene ciloleucel (axi-cel) …

The remarkable clinical activity of chimeric antigen receptor (CAR) therapies in B cell and
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …

Abstract In phase 2 of ZUMA-1, a single-arm, multicenter, registrational trial, axicabtagene
ciloleucel (axi-cel) autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy …

Tebotelimab, a bispecific PD-1× LAG-3 DART molecule that blocks both PD-1 and LAG-3,
was investigated for clinical safety and activity in a phase 1 dose-escalation and cohort …

Axicabtagene ciloleucel (axi-cel) demonstrated superior efficacy compared to standard of
care as second-line therapy in patients with high-risk relapsed/refractory (R/R) large B cell …

CRISPR-based drugs can theoretically manipulate any genetic target. In practice, however,
these drugs must enter the desired cell without eliciting an unwanted immune response, so …

This global phase 3 study compared lisocabtagene maraleucel (liso-cel) with a standard of
care (SOC) as second-line therapy for primary refractory or early relapsed (≤ 12 months) …

Background Patients with relapsed or refractory large B-cell lymphoma after first-line
treatment who are not intended for haematopoietic stem-cell transplantation (HSCT) have …